In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on NLS Pharmaceutics (NLSP – Research Report), with a price target of $4.00. The company’s shares opened today at $1.43.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Oncolytics Biotech, and Actinium Pharmaceuticals. According to TipRanks, McCarthy has an average return of -34.3% and a 17.89% success rate on recommended stocks.
NLS Pharmaceutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on NLS Pharmaceutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company’s tangible assets are held in the United States.
Read More on NLSP:
